Precise Biometrics: All eyes on commercialisation - ABG

Q3 report due Friday, 11 November
We reduce ’23e-’24e sales by 3-1%
Balance sheet set for growth after share issues


Q3’22 expectations

We decrease our Q3’22 sales estimates by 4% due to uncertainties regarding global semiconductor demand. Consequently, our EBITDA estimates are cut by 14% because of the company’s operating leverage. As a result of the recent SEK 44m share issues, the balance sheet will be well-suited for any potential downturn and ready for growth.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/Precise-Biometrics/Equity-research/2022/11/precise-biometrics---all-eyes-on-commercialisation/